Does the media favor IMVT or OCUL?

In the previous week, Ocular Therapeutix had 1 more articles in the media than Immunovant. MarketBeat recorded 9 mentions for Ocular Therapeutix and 8 mentions for Immunovant. Immunovant's average media sentiment score of 0.55 beat Ocular Therapeutix's score of -0.19 indicating that Immunovant is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Immunovant 1 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Ocular Therapeutix 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to PCVX or OCUL?

In the previous week, Ocular Therapeutix had 4 more articles in the media than Vaxcyte. MarketBeat recorded 9 mentions for Ocular Therapeutix and 5 mentions for Vaxcyte. Vaxcyte's average media sentiment score of 0.37 beat Ocular Therapeutix's score of -0.19 indicating that Vaxcyte is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Vaxcyte 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Ocular Therapeutix 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has better valuation and earnings, LNTH or OCUL?

Lantheus has higher revenue and earnings than Ocular Therapeutix. Ocular Therapeutix is trading at a lower price-to-earnings ratio than Lantheus, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Lantheus $1.55B 4.13 $233.56M $4.15 23.61 Ocular Therapeutix $52.04M 34.90 -$265.94M -$1.46 N/A

Does the media favor LNTH or OCUL?

In the previous week, Ocular Therapeutix had 4 more articles in the media than Lantheus. MarketBeat recorded 9 mentions for Ocular Therapeutix and 5 mentions for Lantheus. Lantheus' average media sentiment score of 0.57 beat Ocular Therapeutix's score of -0.19 indicating that Lantheus is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Lantheus 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Ocular Therapeutix 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to KYMR or OCUL?

In the previous week, Kymera Therapeutics and Kymera Therapeutics both had 9 articles in the media. Kymera Therapeutics' average media sentiment score of 0.33 beat Ocular Therapeutix's score of -0.19 indicating that Kymera Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kymera Therapeutics 4 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Ocular Therapeutix 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to SYRE or OCUL?

In the previous week, Ocular Therapeutix had 6 more articles in the media than Spyre Therapeutics. MarketBeat recorded 9 mentions for Ocular Therapeutix and 3 mentions for Spyre Therapeutics. Spyre Therapeutics' average media sentiment score of 1.27 beat Ocular Therapeutix's score of -0.19 indicating that Spyre Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Spyre Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Ocular Therapeutix 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Ocular Therapeutix (OCUL) Competitors

$8.27 -0.66 (-7.42%)

As of 02:13 PM Eastern

Compare

OCUL vs. IMVT, PCVX, LNTH, KYMR, and SYRE

Should you buy Ocular Therapeutix stock or one of its competitors? MarketBeat compares Ocular Therapeutix with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Ocular Therapeutix include Immunovant (IMVT), Vaxcyte (PCVX), Lantheus (LNTH), Kymera Therapeutics (KYMR), and Spyre Therapeutics (SYRE). These companies are all part of the "pharmaceutical products" industry.

How does Ocular Therapeutix compare to Immunovant?

Immunovant (NASDAQ:IMVT) and Ocular Therapeutix (NASDAQ:OCUL) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their media sentiment, earnings, dividends, valuation, institutional ownership, profitability, risk and analyst recommendations.

Immunovant has a net margin of 0.00% compared to Ocular Therapeutix's net margin of -558.24%. Ocular Therapeutix's return on equity of -64.28% beat Immunovant's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immunovant	N/A	-65.66%	-59.88%
Ocular Therapeutix	-558.24%	-64.28%	-48.15%

In the previous week, Ocular Therapeutix had 1 more articles in the media than Immunovant. MarketBeat recorded 9 mentions for Ocular Therapeutix and 8 mentions for Immunovant. Immunovant's average media sentiment score of 0.55 beat Ocular Therapeutix's score of -0.19 indicating that Immunovant is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Immunovant	1 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Ocular Therapeutix	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

47.1% of Immunovant shares are owned by institutional investors. Comparatively, 59.2% of Ocular Therapeutix shares are owned by institutional investors. 1.8% of Immunovant shares are owned by insiders. Comparatively, 2.3% of Ocular Therapeutix shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Ocular Therapeutix has higher revenue and earnings than Immunovant. Immunovant is trading at a lower price-to-earnings ratio than Ocular Therapeutix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immunovant	N/A	N/A	-$505.61M	-$2.78	N/A
Ocular Therapeutix	$52.04M	34.90	-$265.94M	-$1.46	N/A

Immunovant has a beta of 0.76, suggesting that its share price is 24% less volatile than the broader market. Comparatively, Ocular Therapeutix has a beta of 0.93, suggesting that its share price is 7% less volatile than the broader market.

Immunovant presently has a consensus target price of $37.33, suggesting a potential upside of 21.04%. Ocular Therapeutix has a consensus target price of $23.78, suggesting a potential upside of 186.65%. Given Ocular Therapeutix's stronger consensus rating and higher probable upside, analysts clearly believe Ocular Therapeutix is more favorable than Immunovant.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immunovant	1 Sell rating(s)	4 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.45
Ocular Therapeutix	1 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.79

Summary

Ocular Therapeutix beats Immunovant on 13 of the 15 factors compared between the two stocks.

How does Ocular Therapeutix compare to Vaxcyte?

Vaxcyte (NASDAQ:PCVX) and Ocular Therapeutix (NASDAQ:OCUL) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their media sentiment, earnings, dividends, profitability, institutional ownership, risk, analyst recommendations and valuation.

Ocular Therapeutix has higher revenue and earnings than Vaxcyte. Vaxcyte is trading at a lower price-to-earnings ratio than Ocular Therapeutix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vaxcyte	N/A	N/A	-$766.63M	-$6.88	N/A
Ocular Therapeutix	$52.04M	34.90	-$265.94M	-$1.46	N/A

In the previous week, Ocular Therapeutix had 4 more articles in the media than Vaxcyte. MarketBeat recorded 9 mentions for Ocular Therapeutix and 5 mentions for Vaxcyte. Vaxcyte's average media sentiment score of 0.37 beat Ocular Therapeutix's score of -0.19 indicating that Vaxcyte is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Vaxcyte	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Ocular Therapeutix	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Vaxcyte has a beta of 1.3, suggesting that its stock price is 30% more volatile than the broader market. Comparatively, Ocular Therapeutix has a beta of 0.93, suggesting that its stock price is 7% less volatile than the broader market.

Vaxcyte presently has a consensus target price of $86.00, suggesting a potential upside of 82.38%. Ocular Therapeutix has a consensus target price of $23.78, suggesting a potential upside of 186.65%. Given Ocular Therapeutix's stronger consensus rating and higher probable upside, analysts plainly believe Ocular Therapeutix is more favorable than Vaxcyte.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vaxcyte	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63
Ocular Therapeutix	1 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.79

96.8% of Vaxcyte shares are owned by institutional investors. Comparatively, 59.2% of Ocular Therapeutix shares are owned by institutional investors. 3.1% of Vaxcyte shares are owned by insiders. Comparatively, 2.3% of Ocular Therapeutix shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Vaxcyte has a net margin of 0.00% compared to Ocular Therapeutix's net margin of -558.24%. Vaxcyte's return on equity of -32.51% beat Ocular Therapeutix's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vaxcyte	N/A	-32.51%	-29.51%
Ocular Therapeutix	-558.24%	-64.28%	-48.15%

Summary

Ocular Therapeutix beats Vaxcyte on 8 of the 15 factors compared between the two stocks.

How does Ocular Therapeutix compare to Lantheus?

Lantheus (NASDAQ:LNTH) and Ocular Therapeutix (NASDAQ:OCUL) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, earnings, institutional ownership, profitability, dividends, media sentiment, valuation and risk.

Lantheus has higher revenue and earnings than Ocular Therapeutix. Ocular Therapeutix is trading at a lower price-to-earnings ratio than Lantheus, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lantheus	$1.55B	4.13	$233.56M	$4.15	23.61
Ocular Therapeutix	$52.04M	34.90	-$265.94M	-$1.46	N/A

Lantheus has a net margin of 18.05% compared to Ocular Therapeutix's net margin of -558.24%. Lantheus' return on equity of 29.32% beat Ocular Therapeutix's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lantheus	18.05%	29.32%	15.00%
Ocular Therapeutix	-558.24%	-64.28%	-48.15%

Lantheus presently has a consensus target price of $101.86, indicating a potential upside of 3.97%. Ocular Therapeutix has a consensus target price of $23.78, indicating a potential upside of 186.65%. Given Ocular Therapeutix's stronger consensus rating and higher possible upside, analysts clearly believe Ocular Therapeutix is more favorable than Lantheus.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lantheus	0 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.73
Ocular Therapeutix	1 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.79

99.1% of Lantheus shares are held by institutional investors. Comparatively, 59.2% of Ocular Therapeutix shares are held by institutional investors. 1.7% of Lantheus shares are held by company insiders. Comparatively, 2.3% of Ocular Therapeutix shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

In the previous week, Ocular Therapeutix had 4 more articles in the media than Lantheus. MarketBeat recorded 9 mentions for Ocular Therapeutix and 5 mentions for Lantheus. Lantheus' average media sentiment score of 0.57 beat Ocular Therapeutix's score of -0.19 indicating that Lantheus is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lantheus	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Ocular Therapeutix	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Lantheus has a beta of -0.08, indicating that its stock price is 108% less volatile than the broader market. Comparatively, Ocular Therapeutix has a beta of 0.93, indicating that its stock price is 7% less volatile than the broader market.

Summary

Lantheus beats Ocular Therapeutix on 9 of the 16 factors compared between the two stocks.

How does Ocular Therapeutix compare to Kymera Therapeutics?

Kymera Therapeutics (NASDAQ:KYMR) and Ocular Therapeutix (NASDAQ:OCUL) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their media sentiment, valuation, dividends, institutional ownership, profitability, analyst recommendations, earnings and risk.

59.2% of Ocular Therapeutix shares are held by institutional investors. 16.0% of Kymera Therapeutics shares are held by company insiders. Comparatively, 2.3% of Ocular Therapeutix shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Kymera Therapeutics currently has a consensus price target of $118.10, suggesting a potential upside of 58.80%. Ocular Therapeutix has a consensus price target of $23.78, suggesting a potential upside of 186.65%. Given Ocular Therapeutix's higher probable upside, analysts plainly believe Ocular Therapeutix is more favorable than Kymera Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kymera Therapeutics	1 Sell rating(s)	0 Hold rating(s)	20 Buy rating(s)	1 Strong Buy rating(s)	2.95
Ocular Therapeutix	1 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.79

Kymera Therapeutics has a beta of 2.02, meaning that its stock price is 102% more volatile than the broader market. Comparatively, Ocular Therapeutix has a beta of 0.93, meaning that its stock price is 7% less volatile than the broader market.

Ocular Therapeutix has higher revenue and earnings than Kymera Therapeutics. Kymera Therapeutics is trading at a lower price-to-earnings ratio than Ocular Therapeutix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kymera Therapeutics	$51.48M	118.83	-$311.35M	-$3.57	N/A
Ocular Therapeutix	$52.04M	34.90	-$265.94M	-$1.46	N/A

Ocular Therapeutix has a net margin of -558.24% compared to Kymera Therapeutics' net margin of -611.94%. Kymera Therapeutics' return on equity of -24.71% beat Ocular Therapeutix's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kymera Therapeutics	-611.94%	-24.71%	-22.05%
Ocular Therapeutix	-558.24%	-64.28%	-48.15%

In the previous week, Kymera Therapeutics and Kymera Therapeutics both had 9 articles in the media. Kymera Therapeutics' average media sentiment score of 0.33 beat Ocular Therapeutix's score of -0.19 indicating that Kymera Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kymera Therapeutics	4 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Ocular Therapeutix	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Kymera Therapeutics beats Ocular Therapeutix on 9 of the 16 factors compared between the two stocks.

How does Ocular Therapeutix compare to Spyre Therapeutics?

Spyre Therapeutics (NASDAQ:SYRE) and Ocular Therapeutix (NASDAQ:OCUL) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, earnings, risk, profitability, media sentiment, valuation and dividends.

80.4% of Spyre Therapeutics shares are owned by institutional investors. Comparatively, 59.2% of Ocular Therapeutix shares are owned by institutional investors. 15.7% of Spyre Therapeutics shares are owned by insiders. Comparatively, 2.3% of Ocular Therapeutix shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Spyre Therapeutics has higher earnings, but lower revenue than Ocular Therapeutix. Spyre Therapeutics is trading at a lower price-to-earnings ratio than Ocular Therapeutix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Spyre Therapeutics	N/A	N/A	-$155.20M	-$2.08	N/A
Ocular Therapeutix	$52.04M	34.90	-$265.94M	-$1.46	N/A

Spyre Therapeutics has a beta of 3.12, indicating that its stock price is 212% more volatile than the broader market. Comparatively, Ocular Therapeutix has a beta of 0.93, indicating that its stock price is 7% less volatile than the broader market.

Spyre Therapeutics has a net margin of 0.00% compared to Ocular Therapeutix's net margin of -558.24%. Spyre Therapeutics' return on equity of -42.88% beat Ocular Therapeutix's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Spyre Therapeutics	N/A	-42.88%	-27.76%
Ocular Therapeutix	-558.24%	-64.28%	-48.15%

In the previous week, Ocular Therapeutix had 6 more articles in the media than Spyre Therapeutics. MarketBeat recorded 9 mentions for Ocular Therapeutix and 3 mentions for Spyre Therapeutics. Spyre Therapeutics' average media sentiment score of 1.27 beat Ocular Therapeutix's score of -0.19 indicating that Spyre Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Spyre Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Ocular Therapeutix	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Spyre Therapeutics presently has a consensus target price of $90.25, indicating a potential upside of 30.59%. Ocular Therapeutix has a consensus target price of $23.78, indicating a potential upside of 186.65%. Given Ocular Therapeutix's higher probable upside, analysts plainly believe Ocular Therapeutix is more favorable than Spyre Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Spyre Therapeutics	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	3.00
Ocular Therapeutix	1 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.79

Summary

Spyre Therapeutics beats Ocular Therapeutix on 10 of the 16 factors compared between the two stocks.

Get Ocular Therapeutix News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding OCUL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

OCUL vs. The Competition

Export

Metric	Ocular Therapeutix	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.97B	$3.02B	$6.39B	$12.60B
Dividend Yield	N/A	1.97%	2.69%	5.30%
P/E Ratio	-5.88	17.99	21.14	26.64
Price / Sales	34.90	329.94	513.05	95.52
Price / Cash	N/A	55.97	27.44	37.60
Price / Book	2.70	3.90	9.81	6.79
Net Income	-$265.94M	$75.85M	$3.56B	$337.23M
7 Day Performance	0.06%	-0.39%	0.40%	2.67%
1 Month Performance	-12.04%	23.43%	4.87%	6.66%
1 Year Performance	2.28%	25.02%	31.14%	37.99%

Ocular Therapeutix Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
OCUL Ocular Therapeutix	2.7208 of 5 stars	$8.27 -7.4%	$23.78 +187.6%	+11.5%	$1.97B	$52.04M	N/A	230
IMVT Immunovant	2.471 of 5 stars	$34.15 flat	$35.33 +3.5%	+121.0%	$7.01B	N/A	N/A	120	Gap Up
PCVX Vaxcyte	2.7797 of 5 stars	$47.30 flat	$86.00 +81.8%	+50.0%	$6.83B	N/A	N/A	160	Gap Up
LNTH Lantheus	2.2715 of 5 stars	$103.00 flat	$99.71 -3.2%	+28.6%	$6.71B	$1.54B	24.82	1,193
KYMR Kymera Therapeutics	2.2495 of 5 stars	$78.89 flat	$118.10 +49.7%	+166.4%	$6.49B	$39.21M	N/A	170

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:OCUL) was last updated on 6/2/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Ocular Therapeutix (OCUL) Competitors

OCUL vs. IMVT, PCVX, LNTH, KYMR, and SYRE

How does Ocular Therapeutix compare to Immunovant?

Summary

How does Ocular Therapeutix compare to Vaxcyte?

Summary

How does Ocular Therapeutix compare to Lantheus?

Summary

How does Ocular Therapeutix compare to Kymera Therapeutics?

Summary

How does Ocular Therapeutix compare to Spyre Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

OCUL vs. The Competition

Ocular Therapeutix Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Ocular Therapeutix (OCUL) Competitors

OCUL vs. IMVT, PCVX, LNTH, KYMR, and SYRE

How does Ocular Therapeutix compare to Immunovant?

Is IMVT or OCUL more profitable?

Does the media favor IMVT or OCUL?

Do institutionals & insiders hold more shares of IMVT or OCUL?

Which has preferable earnings and valuation, IMVT or OCUL?

Which has more volatility & risk, IMVT or OCUL?

Do analysts recommend IMVT or OCUL?

Summary

How does Ocular Therapeutix compare to Vaxcyte?

Which has better earnings & valuation, PCVX or OCUL?

Does the media refer more to PCVX or OCUL?

Which has more risk & volatility, PCVX or OCUL?

Do analysts recommend PCVX or OCUL?

Do insiders and institutionals hold more shares of PCVX or OCUL?

Is PCVX or OCUL more profitable?

Summary

How does Ocular Therapeutix compare to Lantheus?

Which has better valuation and earnings, LNTH or OCUL?

Is LNTH or OCUL more profitable?

Do analysts recommend LNTH or OCUL?

Do institutionals and insiders believe in LNTH or OCUL?

Does the media favor LNTH or OCUL?

Which has more risk and volatility, LNTH or OCUL?

Summary

How does Ocular Therapeutix compare to Kymera Therapeutics?

Do institutionals & insiders hold more shares of KYMR or OCUL?

Do analysts rate KYMR or OCUL?

Which has more risk and volatility, KYMR or OCUL?

Which has preferable valuation & earnings, KYMR or OCUL?

Is KYMR or OCUL more profitable?

Does the media refer more to KYMR or OCUL?

Summary

How does Ocular Therapeutix compare to Spyre Therapeutics?

Do institutionals & insiders believe in SYRE or OCUL?

Which has better earnings & valuation, SYRE or OCUL?

Which has more risk & volatility, SYRE or OCUL?

Is SYRE or OCUL more profitable?

Does the media refer more to SYRE or OCUL?

Do analysts prefer SYRE or OCUL?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

OCUL vs. The Competition

Ocular Therapeutix Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools